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Original Article

Multiscale Design of Cell-Type–Specific Pharmacokinetic/
Pharmacodynamic Models for Personalized Medicine:
Application to Temozolomide in Brain Tumors
A Ballesta1, Q Zhou2, X Zhang1, H Lv1 and JM Gallo1

Optimizing anticancer therapeutics needs to account for variable drug responses in heterogeneous cell populations within
the tumor as well as in organs of toxicity. To address cell heterogeneity, we propose a multiscale modeling approach—from
in vitro to preclinical and clinical studies—to develop cell-type–specific pharmacokinetic–pharmacodynamic (PK-PD) models.
A physiologically based mechanistic modeling approach integrating data from aqueous solutions, U87 glioma cells, mice, and
cancer patients was utilized to characterize the brain disposition of temozolomide (TMZ), the cornerstone of chemotherapy
against glioblastoma multiforme. The final model represented intracellular normal brain and brain tumor compartments in which
TMZ pH-dependent conversion to the DNA-alkylating species leads to the formation of DNA adducts that serve as an entry point
for a PD model. This multiscale protocol can be extended to account for TMZ PK-PD in different cell populations, thus providing
a critical tool to personalize TMZ-based chemotherapy on a cell-type–specific basis.
CPT Pharmacometrics Syst. Pharmacol. (2014) 3, e112; doi:10.1038/psp.2014.9; published online 30 April 2014
Personalized cancer therapy is a new horizon that offers to
dramatically improve patient responses and early attempts
to tailor chemotherapy are either rooted in a patient’s
genomic signature1–3 or based on systems pharmacological approaches involving protein networks and pharmacokinetic–pharmacodynamic (PK-PD) models.4–7 Regardless
of whether genomic- or protein-centric methods are undertaken, an account of cell heterogeneity is in order. Indeed,
recent analyses have revealed heterogeneity both within the
tumor region—a collection of cell types, such as cancer cells,
tumor stem cells, endothelial cells, and immune cells8—and
within organs of toxicity that may include different healthy cell
types; for instance, bone marrow contains hematopoietic progenitors of different maturities.9 Each cell population may display specific PK-PD characteristics and drug sensitivity that
will impact the overall response.
To address cell heterogeneity, a systems pharmacological
approach utilizing network PK-PD models is proposed as a
comprehensive mean to design patient chemotherapy. We
considered the importance of constructing physiologically
based models with intracellular compartments as this provides relevant PK-PD features that could differentiate drug
action in each cell type. However, the experimental assessment of such cell-type–specific intracellular PK-PD models
remains challenging in a preclinical setting and to a greater
extent in cancer patients. In particular, although one can
readily appreciate that intracellular drug concentrations are
the final input to drug action or PDs, there has been no tangible means to obtain this information in a whole animal. In
this context, we developed a multiscale—in vitro to in vivo—
modeling approach to bridge this gap.
The multiscale modeling protocol was developed for temozolomide (TMZ), the cornerstone of chemotherapy against

glioblastoma multiforme (GBM), the most frequent primary
brain tumor in adults.10,11 GBM therapeutic management
involving surgery, radiation, and chemotherapy has shown
suboptimal advances as patient median survival remains at
12 to 14 months and may benefit from personalized TMZbased chemotherapy. TMZ is a prodrug that spontaneously
converts into its metabolite 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC), which is subsequently degraded
into 4-amino-5-imidazole-carboxamide (AIC)—an inactive
metabolite—and a methyldiazonium cation, the DNA-methylating species.12–14 These reactions are pH-dependent as
TMZ and MTIC degradation rates increase and decrease,
respectively, with pH values.15 The methyldiazonium cation
creates DNA adducts—a marker of TMZ PD—that trigger
DNA damage responses involving the p53 pathway, DNA
repair mechanisms, and potentially cell-cycle arrest and cell
apoptosis.14,16 To initiate the development of cell-type–specific
PK-PD models, we considered a homogeneous population of
glioma cells for the brain tumor that was cast into intracellular
PK models to ultimately specify the brain disposition of TMZ
and its metabolites.
RESULTS
The multiscale approach to design a model of TMZ intracellular brain disposition progressed through the following steps:
(i) TMZ pH-dependent conversion study in solutions, (ii)
in vitro TMZ conversion and transport studies in U87 glioma
cells, (iii) TMZ PK studies in mice, and (iv) TMZ PK studies in
brain tumor patients. They are presented in sequence below.
TMZ pH-dependent conversion
The model of TMZ pH-dependent conversion was derived from
the literature12–14 and represents a stoichiometric degradation
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k T (pH) = k T 0 · eλT pH

of TMZ to its metabolite MTIC—rate constant k T —that subsequently fragments into the methyldiazonium cation and
the inactive species AIC via rate constant k M (Figure 1a,
equations in Supplementary Data). The rates k T and k M
are highly pH-dependent since TMZ is stable at acidic pH but
decomposes to MTIC at more alkaline pH values, whereas
MTIC degradation rate is lower at large pH values and
increases as pH decreases.12,15 They were modeled as:

a

k M (pH) = k M0 · e − λMpH
The instability of the methyldiazonium cation, which is a
highly reactive species was represented by a degradation of
rate constant kcat set to 6,000 h–1 that is equivalent to a halflife of 0.4 s.17 Parameters kT0, λT, kM0, and λM were estimated
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Figure 1 A multiscale approach for mechanistic modeling of TMZ PK. (a) TMZ pH-dependent conversion in solution. Each molecule of
TMZ produces one molecule of MTIC that further degrades into one molecule of AIC, an inactive metabolite, and one molecule of the
methyldiazonium cation which is the methylating agent. (b) TMZ PK and simplified PD model in U87 glioma cells. See Results section for the
definition of mathematical variables and parameters. (c) Model of TMZ brain disposition in tumor-bearing mice and brain tumor patients. The
blood compartment is a forcing function whereas the normal brain and brain tumor compartments are represented by physiologically based
models. See Results section for the definition of mathematical variables and parameters. (d) Prospective cell-type–specific model of TMZ
PK-PD. The brain disposition model can be extended to account for cell heterogeneity both in the tumor region and in the bone marrow, the
main toxicity target of TMZ. The blood and interstitial fluid compartments are directly inferred from the brain disposition model whereas each
cell type are represented by a model of TMZ intracellular PK-PD fitted to in vitro data performed in the corresponding cell population. MTIC,
metabolite 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide; PD, pharmacodynamics; PK, pharmacokinetics; TMZ, temozolomide.
CPT: Pharmacometrics & Systems Pharmacology
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utilizing available TMZ, MTIC, and AIC concentration–time
data in buffer solutions at four pH values (1, 6.8, 9.1, and
13) with an initial TMZ concentration of 1 mmol/l15 (Table 1).
The best-fit model closely agreed with the observed data
(Figure 2a–d).
For TMZ exposures ranging from 2 to 96 h, the percentage of activated TMZ-methylating cation had the form of an
increasing steep S-shape function as pH increased, suggesting that a small pH variation may lead to a significant change
in the TMZ activation rate (Figure 2e). Further, the model
predicted that TMZ activation rate was close to zero at pH
= 4 for any exposure duration and increased with pH values
(Figure 2a–d). Interestingly, although the rate of MTIC fragmentation decreases with pH, the reaction does not prevent
TMZ activation at high pH.
In vitro TMZ PK
The second step of the multiscale approach analyzed TMZ
metabolism, membrane transport and simplified PD in U87
glioma cell culture. Two physiological compartments—extracellular and intracellular—were considered in which TMZ
pH-dependent activation and MTIC subsequent degradation

were represented by the above-described model (Figure 1b).
Because TMZ is highly lipophilic and constitutes a poor substrate of ABC transporters,18 transport of the parent drug and
AIC between the extracellular and intracellular compartments
were modeled as passive diffusion. As MTIC displays limited
ability to cross cell membranes and as the methyldiazonium
cation is a highly reactive species, their transport between
the two compartments were not considered.19 Concerning
TMZ PD, the methyldiazonium cation is the sole species able
to form DNA adducts.12
Since TMZ metabolism is highly pH dependent, we monitored the medium pH ( pHout ) and found an initial increase
followed by a return close to its initial value which was modeled as (Figure 3g):
pHout (t ) = pH0 + e −BpHt − e −CpHt
in which pH0 is the initial pH value, and BpH and CpH are two
phenomenological parameters. Available experimental data
in U87-cultured cells from20 allowed us to derive the following
formula for the intracellular pH (pHin) (see Supplementary
Data): pHin = pHout − 0.01

Table 1 Model parameters
Parameters (unit)

Reaction

Buffer
solutions

Cell
culture

Mice

Humans

Metabolism
kT0 (h−1)

TMZ metabolism into MTIC

λT (h−1)
kM0 (h−1)

1.1 × 10−7
1.96

MTIC degradation into AIC

λM (h−1)

2.09 (0.02)

292
0.33

0.31 (0.26)

TMZ transport
Naive
0.039 (16.9)

17.5 (16.9)

0.081 (17)

36.32 (17)

0.127 (16.9)

507.2 (16.9)

Estimated

pT, pTtumor (l.h−1)

TMZ brain tumor influx

0.0038 (16.9)

tumor
pT2, pT2
(l.h−1)

TMZ brain tumor efflux

0.008 (17)

pTbrain (l.h−1)

TMZ normal brain influx

brain
pT2
(l.h−1)

TMZ normal brain efflux

0.154 (51.9)

620.3 (51.9)

qTtumor (l.h−1)

TMZ blood to tumor interstitial fluid transport

0.21 × 10−3 (22.4)

0.094 (22.4)

0.019 (122)

tumor
qT2
(l.h−1)

TMZ tumor interstitial fluid to blood transport

0.15 × 10−3 (47.4)

0.067 (47.4)

0.069 (170)

qTbrain (l.h−1)

TMZ blood to normal brain interstitial fluid transport

0.24 × 10−3 (29.2)

0.97 (29.2)

0.197 (122)

brain
qT2
(l.h−1)

TMZ normal brain interstitial fluid to blood transport

0.49 × 10−3 (47.4)

1.97 (47.4)

2.004 (170)

In vitro experiments
TMZ0 (µmol/l)

Initial TMZ concentration

59.2 (0.04)

pA (l.h−1)

AIC U87 cell influx

0.0034 (28.5)

pA2 (l.h−1)

AIC U87 cell efflux

0.0072 (28.5)

pH0

Initial medium pH

7.57 (0.02)

BpH (h−1)

pH parameter

14.6 (0.56)

CpH (h−1)

pH parameter

998.3 (1.4)

In vivo blood forcing function
C0 (µmol/l)

Initial TMZ gut concentration

2330.6 (5.5)

334.6 (107.2)

Ka (h−1)

First-order absorption

0.64 (28.1)

0.398 (35.2)

kclear (l.h−1)

First-order elimination

18.7 (30.5)

2.73 (99.2)

Pharmacodynamics
kadd (h−1)

DNA adducts formation rate

1.81 (0.33)

Fixed parameters
kcat (h−1)

Methylating cation degradation

6,000

Mean values (%CV) are shown. Bold numbers indicate that parameters were scaled from the previous scale.
AIC, 4-amino-5-imidazole-carboxamide; MTIC, metabolite 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide; TMZ, temozolomide.
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Figure 2 TMZ pH-dependent conversion in buffer solutions. (a–d) TMZ, MTIC, and AIC concentration–time profiles in buffer solutions at
indicated pH. Solid lines and dots correspond respectively to the best-fit profiles and data from ref. 15 of TMZ (black), MTIC (orange), and AIC
(yellow). (e) Total methylating cation, defined as the sum of the cation C and all products of its degradation, with respect to buffer solution pH
for different exposure duration. AIC, 4-amino-5-imidazole-carboxamide; MTIC, metabolite 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide;
TMZ, temozolomide.

The final model (Figure 1b, equations in Supplementary Data) required 14 parameters to be determined: 4
parameters for TMZ pH-dependent metabolism (kT0, λT,
kM0, λM), 4 transport rate constants (pT, pT2, pA, pA2), 3 pH
parameters (pH0, BpH, CpH), the degradation rate of the
cation kcat,1 PD parameter (kadd) and the initial TMZ extracellular concentration from the U87 cell studies (TMZ0).
Parameters kcat, kT0, and kM0 were directly inferred from
the buffer study whereas λT and λM were estimated for the
in vitro system allowing a 50% deviation from the buffer
solution values. The 11 remaining parameters were estimated by fitting TMZ, MTIC, and AIC extra- and intracellular concentration–time data and extracellular pH results in
U87 cells together with available PD data from which it was
estimated that an exposure of TMZ at 800 µmol/l during
CPT: Pharmacometrics & Systems Pharmacology

1 h led to a DNA adduct concentration of 70 nmol/l in the
absence of DNA repair mechanisms21 (see Supplementary
Data).
Agreement between fitted profiles and observed values
together with low %CV of parameter estimates support model
validity (Figure 3; Table 1). TMZ exposure led to increasing
concentrations of AIC. DNA adduct concentration was predicted to increase as no repair mechanisms were considered
in this model.
TMZ brain disposition in mice
The next step consisted of designing a mechanistic PK
model of TMZ in brain, based on two complementary investigations; a microdialysis study in normal mice, which provided serial measurements of TMZ plasma and normal brain
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Figure 3 TMZ PK in U87 cell culture. (a–f) TMZ, MTIC, and AIC extra- and intracellular concentration–time profiles. Dots represent
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interstitial fluid concentrations, and a steady-state investigation in which TMZ plasma, whole brain, and brain tumor
concentrations were measured in mice bearing intracerebral
U87 tumors.
Because we focused on TMZ brain disposition, its blood
concentration Tblood was accounted for by a forcing function (Figure 1c) chosen as the best-fit to the plasma measurements from the microdialysis mouse study assuming a
blood:plasma TMZ concentration ratio of 122,23:
dTblood
= C 0K ae −K at − k clearTblood
dt
where C0, Ka, and kclear are the initial TMZ gut concentration,
the first-order absorption rate constant, and the first-order
elimination rate constant, respectively. C0 was computed
for each individual mouse as the total administered dose

divided by the gut volume, assumed equal to 1.7 ml,24
whereas Ka and kclear were estimated from plasma data
(Table 1; Figure 4a).
The normal brain and brain tumor were assumed to be constituted of homogeneous normal and U87 glioma cell populations, respectively, and were represented by physiologically
based PK models, which consisted of interstitial and intrabrain
brain
tumor
cellular compartments of volume Vinter
, Vintra
, and Vinter
tumor
, Vintra (Figure 4a). Utilizing the model designed in the buffer solution study, TMZ pH-dependent metabolism into MTIC
was represented in all brain compartments, whereas MTIC
and the methylating agent—which were assumed unable to
diffuse from one compartment to another—were only explicitly modeled in the intracellular compartments in which the
methylating cation creates DNA adducts at the rate kadd. The
metabolic parameters kcat, kT0, λT, kM0, λM and the PD rate
www.nature.com/psp
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kadd were directly inferred from the U87 cell study. pH values
were assumed identical in the normal brain and tumor region,
as experimentally demonstrated in humans25, and were set
to 7.2 in the intracellular compartment, 7.3 in the interstitial
fluid, and 7.4 in the blood.24,26
The tumor cell membrane transport parameters pTtumor and
tumor
pT2
were computed by scaling the in vitro parameters pT
and pT2 using the following formulas, which suppose that
the contact surface between the cells and the extracellular
medium was proportional to the total cell volume:
pTtumor = pT ·

tumor
Vintra
V tumor
tumor
and pT2
= pT2 · intra
Vin
Vin

tumor
in which Vin is the in vitro intracellular volume, and Vintra
the tumor intracellular volume computed as a fraction of the
tumor
tumor
= fintra · Vtotal
total tumor volume: Vintra
.
brain
brain
The six remaining parameters q Tbrain, q T2
, pTbrain, pT2
,
tumor
tumor
and q T , q T2
were estimated by utilizing the microdialysis and steady-state mouse studies. Since these
datasets were not sufficient to ensure unique parameter
estimates, two constraints were added assuming that drug
transport from interstitial fluid to intracellular medium, and
from interstitial fluid to blood, were equivalent in the brain
tumor and normal brain such that: p brain = Vbrain · p tumor and
T
T
V
Vtumor
brain
tumor .
q T2
= brain · q T2
Vtumor

CPT: Pharmacometrics & Systems Pharmacology

While TMZ microdialysis normal brain interstitial fluid
measurements were directly compared to the corresponding model variable, whole normal brain and brain tumor
TMZ concentrations did not explicitly appear in the model
and were computed as follows. We assumed that the normal
brain and tumor were exclusively constituted of blood, interstitial fluid, and intracellular components with respective volume fractions fblood , finter , and fintra set to 2, 20, and 78% for
the normal brain and 5, 30, and 65% for the tumor.27–29 TMZ
concentrations in the whole normal brain or tumor can then
be computed as (omitting superscripts for normal brain and
tumor): Ttotal = fbloodTblood + finterTinter + fintra Tintra . During steadystate administration, TMZ concentrations in brain compartments rapidly reached quasi-steady state, as suggested
by the data and adjoining simulations, and were computed
pT
as: Tintra
with A =
and
* = A ⋅ Tinter
* ,Tinter
* = B ⋅ Tblood
*
pT2 + k Tintra
qT
B=
where Tblood
was set
*
V
V
q T2 + k Tinter + pT intra − pT2 intra A
Vinter
Vinter
to the steady-state plasma measurement in each mouse.
Volumes Vinter and Vintra were computed for the normal brain
and the tumor as Vinter = finterVtotal and Vintra = fintraVtotal, the
whole normal brain volume being set to 360 μl,24 and the
tumor volume to 111.5 µl, its mean value in the steadystate study. Then, TMZ steady-state total concentration
* = (fblood + finter A + fintra AB ) ⋅ Tblood
* .
was computed as: Ttotal
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the best-fit model with estimated parameters. In (b), open diamonds are TMZ normal brain concentrations from microdialysis measurements
in patients,31 which are shown in greater details in the inset, together with TMZ normal brain interstitial concentration best-fit profile. (f) Global
analysis of parameter sensitivity on drug efficacy in brain tumor (see Results and Methods). PK, pharmacokinetics; TMZ, temozolomide.

The parameter estimation procedure consisted of two
independent steps leading to the estimation of, first, q Tbrain ,
brain
brain
q T2
, and pT2
and secondly q Ttumor (Table 1). Normal brain
parameters were estimated by combining TMZ whole normal brain and brain microdialysis measurements as follows.
Since the steady-state and microdialysis studies were performed in 7 and 10 mice respectively, a parameter set was
estimated for each of the 70 possible pairs composed of one
individual of each study, by fitting the individual steady-state
normal brain and plasma TMZ concentrations together with
the individual normal brain interstitial TMZ concentrations,
setting the blood forcing function parameters to their values
estimated for the corresponding mouse of the microdialysis investigation. The resultant 70 parameter sets were then
used to calculate the mean and %CV of each parameter.
Finally, q Ttumor was independently estimated by fitting individual steady-state plasma and whole tumor concentrations,
and computing the mean and %CV of individual parameters.
The model best fit and experimental data agreed (Figure 4).
Both in the normal brain and tumor, transport parameters
between interstitial and intracellular compartments were
three orders of magnitude greater than the ones between
blood and interstitial fluid (Table 1). Intracellular transport
was faster in the normal brain than in the tumor, however
tumor
brain
parameter ratios pT2
and pT2 were in the same range.
tumor
brain
pT
pT

tumor
brain
q T2
q T2
was 2.5-fold lower than
which was
tumor
brain
qT
qT
consistent with BBB disruption in the tumor often reported
in the literature.30 As a consequence, best-fit TMZ interstitial and intracellular concentrations were nearly equivalent in
the normal brain with an area under the curve (AUC) ratio of
1.2, whereas, in the tumor, TMZ interstitial concentration was
greater than the intracellular concentration as reflected by an
AUC ratio equal to 2.08. Finally, the TMZ intracellular AUC
was 1.7-fold greater in the brain tumor than in the normal brain which led to a 1.8-fold higher final DNA adduct
concentration (Figure 4).

TMZ PK in brain tumor patients
The final step of our multiscale approach was directed at
predicting TMZ brain disposition in brain tumor patients. For
the human study, the structure of the mouse model was kept
identical and parameters were adapted as follows. First, the
blood forcing function parameters were determined from
mean and standard deviation values of TMZ plasma concentrations available in seven brain tumor patients after a single
oral dose of 150 mg/m2.31 Parameters of TMZ metabolism
(kcat, kT0, λT, kM0, and λM) and PD (kadd), as well as pH values
and brain and tumor volume fractions were inferred from the
mouse study. Volumes of whole normal brain and brain tumor
www.nature.com/psp
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were set to 1.45 l24 and 0.05 l,32 respectively. Cell membrane
transport parameters were scaled up from mice to humans
by assuming that the contact surface between interstitial and
intracellular mediums was proportional to the cell volume
such that:

In vitro
Xout

Data-driven
model design

Xin

p human = p mouse ·
- Interstitial/intracellular model structure
- Fixed/scaled parameters and parameter ranges

Preclinical
Data-driven
model design

B
L
O
O
D

Cell type 1

Cell type n

- Whole-body/tissue-specific model structure
- Fixed/scaled parameters and parameter ranges

brain
tumor
where p stands for pTbrain, pT2
, pTtumor , or pT2
, and Vintra
for the normal brain or tumor intracellular volume.
Transport parameters from blood to interstitial fluid were
either directly scaled up from the mouse study—referred to
as the naive estimation—or estimated using TMZ normal
brain concentrations measured by intracerebral microdialysis in the same seven patients from whom plasma measurements were available.31 For the naive parameter scale-up, the
following formula was used, which assumes that the contact
surface between the blood and the interstitial fluid was proportional to the volume of the blood vessels:

q human = q mouse ·
Clinical
Parameterization
for humans

B
L
O
O
D

Cell type 1

Cell type n

human
Vintra
mouse
Vintra

human
Vblood
mouse
Vblood

brain
tumor
where q stands for q Tbrain, q T2
, or q T2
and Vblood
for the volume of the blood compartment in the normal brain or tumor. For the parameter estimation based
brain
on human data, q Tbrain and q T2
were computed by fitting the model to the brain microdialysis TMZ concentrations from patients. Tumor parameters were subsequently
V
tumor as in the
brain
deduced by assuming, that q T2
= brain ·q T2

Vtumor

- Population parameter estimates

Individual patient
Partial
re-parameterization

B
L
O
O
D

Cell type 1

Cell type n

Personalized drug combination
and administration scheme

Figure 6 A multiscale approach to design cell-type–specific PK,
pharmacokinetics–PK, pharmacodynamics (PK-PD) models for
personalized medicine. The in vitro study is based on experimental
drug investigations in solutions and in cell culture which allow the
design and calibration of a mathematical model describing the
extracellular and intracellular drug PK-PD. Next, for the preclinical
scale, the model of the interstitial and intracellular compartments
is directly inferred from the in vitro study and parameters are either
kept identical, scaled or estimated utilizing whole animal or tissuebased investigations that in our case included two separate studies:
normal brain microdialysis and brain tumor orthotopic studies. This
step allows the design and calibration of a whole-body or tissue
model that designate specific tissues and cells of interest. For
humans, the whole-body model or specific tissue structure remains
CPT: Pharmacometrics & Systems Pharmacology

mouse study and that the ratio between brain and tumor
BBB permeability was identical in mice and in humans:
tumor
brain
tumor
q T,mouse
Vtot
al,mouse Vtotal,human
tumor
brain
q T,human
= q T,human
(Table 1).
brain
brain
tumor
q T,mouse Vtotal,mouse Vtotal,human
Naive scale-up overestimated TMZ concentrations in the
normal brain and tumor as AUC values of best-fit TMZ interstitial and intracellular concentrations were on average 5.1fold greater than the ones of the human data-fitted model
(Figure 5a–e). Concerning the human data-fitted model, the
brain
tumor
q T2
q T2
ratio tumor was 2.8-fold lower than brain which suggested a
qT
qT
disruption of the BBB in the tumor region as in the mouse
study. Interestingly, the ratios between TMZ interstitial and
intracellular AUC were the same in the preclinical and human
data-fitted simulations. As a consequence of having inferred
from the mouse study the ratios between brain and tumor
transport parameters, TMZ intracellular AUC ratio between
brain and tumor was close to the preclinical one as it was
equal to 1.7, leading to a 1.7-fold higher final DNA adduct
concentration in the tumor compared to the normal brain
(Figure 5). The %CV of parameters were relatively high due
to the inherent variability of the clinical data that was utilized for parameter estimation (Figure 5a,b; Table 1). Next,
we performed a global sensitivity analysis to determine the
and parameters are either kept identical, scaled from the preclinical
study or estimated from clinical data in order to compute an average
population parameter set. Finally, the human model is partially
re-parameterized from available data on the individual patient and
utilized in optimization procedures which provide personalized drug
combinations and administration schemes.

Cell-Type–Specific Temozolomide PK/PD Modeling
Ballesta et al.

9

important parameter regarding the efficacy of TMZ computed
as the AUC of DNA adduct concentration in the tumor. The
tumor
parameter q T2
which corresponds to the BBB had the
highest influence followed by kclear, TMZ clearance rate in the
plasma (Figure 5f).
DISCUSSION
In this study, we undertook a multiscale approach to quantitatively characterize TMZ brain disposition in patients. Physiologically based mechanistic models were used to describe at
the molecular scale the biochemical events determining TMZ
PK. The main challenge of this type of modeling lays in the
estimation of the model parameters which may not be directly
measurable from clinical investigations. However, since those
parameters do have a physical meaning and correspond to
biochemical reactions, one may evaluate them independently
in in vitro and in vivo studies and subsequently scale them to
patients (Figure 6). Once population parameters are determined for humans, the model can be partially reparameterized for a specific patient allowing the design of personalized
drug combinations and administration scheme.
To arrive at the final TMZ brain disposition model, a pipeline
of in vitro and in vivo investigations were needed that consisted of four main scales; in vitro aqueous solution and U87
glioma cell studies to characterize membrane transport and
metabolism, in vivo mouse studies that allowed designing and
calibrating the brain disposition model, and finally the clinical
investigation for which the mouse model structure was maintained yet revised by parameter estimation. At each step, the fitted models closely agreed with the observed data and yielded
reliable parameter estimates (low %CV) which supports the
use of this multiscale strategy. It should be appreciated that
the sole use of either the microdialysis or steady-state mouse
studies would not have provided reliable parameter values,
and without the in vitro studies, TMZ membrane transport and
metabolism would not have been accurately estimated.
The current TMZ brain disposition model, whose tumor
intracellular compartment represents a homogenous population of glioma cells, can be extended by considering several
intracellular compartments within the tumor, thus representing different cell types, that may have important roles in tumor
progression, therapeutic targets, and drug resistance.8 Further, models of organs of toxicity, again with subpopulations
of cells of different susceptibilities, could be used in conjunction with the cell-type–specific tumor models to refine drug
treatment regimens. This can readily be appreciated for TMZ
whose main dose-limiting toxicity of myelosuppression could
be considered by adding to the model bone marrow compartments representing hematopoietic stem and progenitor cells.
A hypothetical representation of such model is provided in
Figure 1d in which the blood and interstitial fluid compartments drive the dynamics of different intracellular compartments; highlighted in tumor and bone marrow. This type of
intracellular PK-PD models including both target and toxicity
organs provides a quantitative tool to evaluate therapeutic
indices in a mechanistic manner.
It is appreciated that deriving a multiple cell-type model
will require in vitro investigations—as done here for glioma
cells—to delineate PK-PD behavior in cell types of interest.

Apart from the direct use of in vitro cell studies, isolation of
different cell fractions from ex vivo samples may be afforded
by cell sorting.33 While drug concentrations may be altered
by cell sorting procedures, certain PK-PD features especially
slowly reversible or irreversible endpoints such as apoptosis, may not be unduly altered. Sorting untreated xenograft
tumors into specific cell fractions provides an alternate means
to initiate in vitro PK-PD studies, and when coupled to brain
microdialysis and whole tissue studies as done here provide
the means to obtain cell-type–specific models. Approaches
to dissect bone marrow into hematopoietic stem and progenitor cells could include collection of bone marrow from mice or
collection of ex vivo patient samples that can be cultured for
further drug studies.34,35 Thus, the development of cell-type–
specific PK-PD models is feasible and likely to benefit from
further technical innovations to enable multiscale strategies.
Personalized medicine and inherent tumor heterogeneity provide strong motivation to pursue the development of
cell-type–specific intracellular PK-PD models. The proposed
pipeline of investigation is offered here as an essential first
step to achieve this goal that should contribute to understanding drug action among heterogeneous cell types.
METHODS
In vitro cellular PK studies of TMZ.
U87 human glioma cells (ATCC, Manassas, VA) were cultured
in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum, 100 units/ml penicillin, and 100 units/
ml streptomycin and maintained in a humidified atmosphere of
5% CO2 in air at 37 °C. For PK experiments, 106 cells were
seeded onto 60 mm Petri dishes, cultured overnight and TMZ
(50 µmol/l) added, and the dishes sampled for 2 h. At each time,
dishes were placed on ice instantly, and 1 ml of medium was
collected and kept on ice while the reminder of the medium was
aspirated. The cells were washed twice with 1 ml of cold phosphate-buffered saline, scraped in 200 µl of cold MeOH and kept
on ice. For the detection of TMZ which is stable at pH < 4, 10 µl
of medium was transferred into 300 µl of acid internal standard
solution (0.1 µg/ml dacarbazine and 0.1% formic acid in MeOH)
and 90 µl of MeOH. Another 10 µl of medium was transferred
into 300 µl of internal standard solution without formic acid and
90 µl of MeOH for MTIC and AIC detection which are more
stable at alkaline pH. The cells were sonicated (6 s, three times)
and 20 µl of cell lysate were added to 60 µl of internal standard solution with or without formic acid as for medium samples
and kept on dry ice. For pH measurements, cells were incubated with TMZ (50 µmol/l) and the medium pH was instantly
measured. All medium and cell lysate samples for TMZ, MTIC,
and AIC were analyzed on the same day by high-performance
liquid chromatography–tandem mass spectrometry (LC/MS/
MS) using the multiple reaction monitoring mode specific to
each analyte and the internal standard. The LC/MS/MS system (described in Supplementary Tables S1-S3 online) was
optimized for each compound in positive ionization mode. The
analytical methods were specific and sensitive with a lower limit
of quantification of 0.01 µmol/l. The intraday and interday variabilities were less than 15% in all matrixes. The average run
time was ~5 min. Raw mass spectrometry measurements were
normalized to 1 million of cells (see Supplementary Data).
www.nature.com/psp
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Microdialysis experiments in nude mice.
Four days before mice entered the PK study, a normal brain
microdialysis guide cannula was implanted similar to that previously described for rats.32 One day before the PK sampling, a
catheter was inserted into the right carotid artery of each mouse
under isoflurane anesthesia for blood sampling. On the day of
and prior to TMZ administration, the dummy cannulas were
replaced by microdialysis probes (MRB-1–5; Bioanalytical Systems, West Lafayetter, IN) and the probe TMZ recovery values
were determined using the retrodialysis method as described
previously with minor modifications.32 The flow rate was maintained at 1 µl/min during the washout and microdialysate fractions were automatically collected into individual 250-µl plastic
vials containing 5 µl of 0.1% formic acid every 20 min with a
CMA/170 refrigerated fraction collector. The percent relative
recovery of TMZ from the normal brain was 8.1 ± 1.0%. Animals
were given a single oral dose of 20 mg/kg of TMZ with blood
samples (15 µl) collected over 6 h. Plasma was separated by
centrifugation and stored at −80 °C until analysis. TMZ concentrations in plasma and normal brain microdialysate samples were
determined using a validated reversed-phase high-performance
liquid chromatography method with ultraviolet detection.36

Evolution Strategy algorithm.40,41 For the U87 and patient
studies, Monte Carlo simulations were utilized to compute
parameter estimates and %CV (see Supplementary Data).
For the global sensitivity analysis of the human model, all
parameters’ lower and upper bounds were set to 100-fold
lesser and greater than their estimated values and 18,000
parameter sets were generated from cross-sampling by Saltelli’s extension of Sobol’s method using the MOEA framework (version 2.0).42 For each parameter set, the AUC of
DNA adduct concentration in the tumor during the 18 h following an oral dose of TMZ of 150 mg/m2 was calculated using
Matlab. Finally, parameters’ total-order sensitivity indices and
their confidence intervals were computed using the Sobol
analysis of the MOEA framework.

Steady-state experiments in nude mice.
A previously described orthotopic mouse model of human
glioma was used with minor modifications.37 Briefly, anesthetized NIH-Swiss nude mice (nu/nu) were secured in a stereotaxic instrument, and a 1.5 cm longitudinal incision was made
to expose the skull. Using a sterile 10-μl Hamilton syringe with
a 26-gauge needle attached to the stereotaxic frame, U87MG
cells (1 × 106) in 10 μl of saline were injected 2.5 mm deep into
the left caudate putamen over a 5-min period. The skin was
sutured to close the wound. After surgery, animals were returned
to their cages and received a regular diet and water ad libitum.
Twenty-four days after tumor cell implantation, tumorbearing mice were prepared for aseptic surgery to introduce
a right carotid artery cannula for intraarterial infusion of TMZ
(dissolved in 0.9% NaCl containing 25% dimethyl sulfoxide)
administered the next day over 180 min at a rate of 133.3 μg/kg/
min preceded by a tail veil injection of 7.6 mg/kg of TMZ; both
designed to achieve steady-state plasma concentration of ~17
μg/ml.37 At the end of the infusion, mice were anesthetized and
blood samples were taken from the vena cava. Plasma was
prepared by centrifugation of the heparinized blood and stored
at −80 °C. After the animals were sacrificed, normal brain tissues and brain tumors were immediately excised, snap frozen
on dry ice and stored at −80 °C. TMZ concentrations in plasma,
normal brain, and brain tumor homogenates were determined
using a validated reversed-phase high-performance liquid
chromatography method with ultraviolet detection.36
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Model development, parameter estimation, and sensitivity analysis.
TMZ PK models are based on ordinary differential equations,
which were solved by the Matlab function odes15 (Mathworks, Natick, MA). Chemical reactions were modeled by
the law of mass action and passive drug transport by Fick’s
first law of diffusion.38,39 Parameter estimation was performed
using a weighted least square approach in which the cost
function was minimized by the Covariance Matrix Adaptation
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?

33 Although it has been experimentally demon-

strated that heterogeneous cell populations
both within the brain tumor and the organs of
toxicity displays different drug response, there
has not been any modeling effort to optimize
temozolomide (TMZ) chemotherapy on a celltype–specific basis.

WHAT QUESTION THIS STUDY ADDRESSED?

33 This study aims at designing a physiologically

based model of TMZ brain disposition through
a multiscale modeling approach, thus providing a critical tool towards the personalization of
TMZ-based treatments.

WHAT THIS STUDY ADDS TO OUR KNOWLEDGE

33 This study presents the first mechanistic model

of TMZ brain disposition in mice and in brain
cancer patients, and provides a reliable basis to
design cell-type–specific models of TMZ PK-PD.

HOW THIS MIGHT CHANGE CLINICAL
PHARMACOLOGY AND THERAPEUTICS

33 Cell-type–specific models of TMZ PK-PD may

be used as comprehensive tools to personalize
TMZ-based chemotherapies allowing the design of optimal drug combinations and administration schedules for individual patients.
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